• Vaccine Name: gp140, Gag and Tat Protein Vaccine with MF59
• Target Pathogen: Human Immunodeficiency Virus
• Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
• Vaccine Ontology ID: VO_0004238
• Type: Subunit vaccine
• Status: Research
• Antigen: gp140, Gag and Tat recombinant proteins (Bråve et al., 2007).
• Adjuvant: MF59 vaccine adjuvant
  • Adjuvant name: MF59 vaccine adjuvant
  • VO adjuvant ID: VO_0001301
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: C57Bl/6
• Vaccination Protocol: The protein vaccine component consisted of 20 μg ro-gp140 delivered in the right tibialis muscle and 20 μg rGag and 5 μg rTat delivered in the left tibialis muscle. The proteins were formulated in 50% MF59 solution. Mock treatment consisted of MF59 adjuvant alone or empty DNA plasmid alone (Bråve et al., 2007).
• Challenge Protocol: Briefly, 3 weeks after the final immunization (week 12), the animals were injected intraperitoneally with 1 million syngeneic splenocytes infected with HIV-1/MuLV of subtype B (LAI) (Bråve et al., 2007).
• Efficacy: 83% of mice were tested negative for HIV-1 after challenge (Bråve et al., 2007).